The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
G. Saturno(Cancer Research UK Manchester Institute), Caroline J. Springer(Cancer Research Center), Alfonso Zambon(University of Modena and Reggio Emilia), Filipa M. Lopes(Cancer Research UK), Udai Banerji(Institute of Cancer Research), L. Johnson(Michigan State University), Malin Pedersen(Institute of Cancer Research), Richard Marais(Macclesfield College), Dan Niculescu‐Duvaz(Institute of Cancer Research), Natasha Preece(Institute of Cancer Research), Ion Niculescu‐Duvaz(Institute of Cancer Research), Denys Holovanchuk(Cancer Research UK Manchester Institute), Nathalie Dhomen(Institute of Cancer Research), Paul Lorigan(Manchester Academic Health Science Centre), Amaya Virós(Cancer Research Center), James Larkin(Trinity College Dublin), Matthew Krebs(Christie's), Robert McLeary(Cancer Research UK), Cyril Fisher(Royal Marsden Hospital), Rebecca Lee(Broughton Hospital), E. Dean(University of Manchester), Martin Gore(Imperial College London), Lawrence Davies(Institute of Cancer Research)
Cited by 21
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k